ENGN (enGene Holdings Inc) Sof foyda

ENGN (enGene) - kompaniyaning tovar belgisi

Grafikda ko'rsatilgan enGene Holdings Inc. (ENGN) ning joriy aksiya narxi, ko'rsatkich -0.13 darajasida bo'lgan holda, rahbariyatning hamkorlarni jalb qilish va yangi dori vositalari sinovlarini ilgari surish borasidagi sa'y-harakatlari bilan bog'liqdir. enGene Holdings Inc. (ENGN) immunitetni kuchaytiruvchi agentlar va innovatsion terapiyalarni ishlab chiqishga ixtisoslashgan. Bunday mahsulotlarni ishlab chiqish eksklyuziv patentlar va xavfsizlik uchun ulkan xarajatlarni talab qiladi, bu esa sanoatda kirish uchun yuqori to'siqlarni yaratadi.

ENGN (enGene Holdings Inc.) Sof foyda tarixi 21.02.2024dan 01.11.2026gacha

enGene (ENGN) kompaniyasining tahliliy kesimlari va maʼlumotlar hisoboti

- narx va narxlar bo'yicha konsensus prognoz:
Aksiya kotirovkalari enGene Corp|ENGN - Tahlilchilar konsensus prognozi
- biznesning bozor baholash ko'rsatkichlari:
Bozor kapitallashuvi enGene Corp|ENGN - Kompaniyani butunlay sotib olishdagi haqiqiy narx
- balans kapitallashuvi bo'yicha ma'lumotlar:
Aksiyaning buxgalteriya qiymati enGene|ENGN - Balans kapitallashuvi|Balans qiymatiga nisbatan bozor kapitallashuvi engene.com|ENGN - Kompaniyaning jami aktivlari
- qarzlar va to'lov qobiliyati haqida ma'lumot:
Umumiy qarzning xususiy kapitalga nisbati enGene Holdings Inc.|ENGN - Uzoq muddatli qarzning o'z kapitaliga nisbati|Qisqa muddatli qarzning o'z kapitaliga nisbati enGene Holdings Inc|ENGN - Kompaniyaning umumiy qarzi|Balans kapitallashuviga qarzlar enGene Corp|ENGN - Kompaniyaning uzoq muddatli qarzi|Kompaniyaning qisqa muddatli qarzdorligi enGene|Shoshilinch likvidlik engene.com
- sof daromad va qiymat multiplikatorlari ko'rsatkichlari:
ENGN - Sof foyda
Kompaniyaning jamlanma tahlili:enGene Holdings Inc.
enGene Bio asosiy tovari

enGene Holdings Inc. foydasi biznesning haqiqiy qiymatini aniqlash uchun foydalaniladigan operatsion samaradorlikning kunlik hisob-kitobini ifodalaydi. Investorlar ushbu ko'rsatkichdan uzoq muddatli o'sish potentsialining ob'ektiv belgisi sifatida foydalanadilar. Kompaniyaning sof foydasini tahlil qilish enGene Holdings Inc. rivojlanish trayektoriyasini kuzatish imkonini beradi. Jori narxlar dinamikasi gen terapiyasiga bo'lgan talabning barqarorligini aks ettiradi, garchi ko'rsatkichlarning tez-tez uchraydigan tebranishlari logistik uzilishlar yoki patent risklaridan dalolat berishi mumkin bo'lsa-da.

Asosiy raqobatchilar

Sof daromad argenx BVBA|BNTX (BioNTech SE) - Sof foyda|Sof foyda Abivax Pharma|Sof daromad ADMA (ADMA Biologics, Inc.)|PTGX (Protagonist Therapeutics, Inc.) - Yakuniy foyda|Sof foyda IMVT (Immunovant Corp)|Sof moliyaviy natija Kiniksa Corp (KNSA)|GRFS - Kompaniyaning sof foydasi|adaptivebiotech.com (ADPT) - Sof daromad|Celldex Therapeutics, Inc. (CLDX) - Kompaniyaning sof foydasi|Sof daromad Aurinia Pharmaceuticals Inc|Sof daromad BCRX|Sof foyda Vera Corp|Kompaniyaning sof foydasi Dianthus Therapeutics (DNTH)|pharvaris.com - Kompaniya foydasi|Sof foyda ABCL (AbCellera Biologics Inc)|Tourmaline Bio Inc (TRML) - Kompaniyaning sof daromadi|Intrexon - Sof foyda|Kompaniyaning sof daromadi Pharming Corp|Nektar Therapeutics (NKTR) - Kompaniyaning sof foydasi|Kompaniya foydasi UPB|ZBIO (Zenas Biopharma) - Sof foyda|IMNM - Yillik sof foyda|Sof foyda GOSS|KALV - Kompaniyaning sof daromadi|Kompaniyaning sof foydasi Septerna Inc SEPN|PVLA: Kompaniya foydasi|Savara - Sof foyda|Kompaniyaning sof daromadi Rigel Pharma|ANAB (AnaptysBio Corp) - Sof daromad|Astria Corp - Yakuniy foyda|RAPT (RAPT Therapeutics, Inc.) - Sof foyda|JBIO: Yakuniy foyda|Kompaniyaning sof foydasi Aclaris Therapeutics, Inc. (ACRS)|KYTX - Kompaniyaning sof daromadi|Kompaniyaning sof foydasi Tiziana Life Sciences PLC TLSA|Cabaletta Bio Inc - Kompaniyaning sof foydasi|Ventyx Biosciences - Sof foyda|THTX (theratech.com) - Kompaniya foydasi|AVTX: Sof foyda|ELDN - Sof moliyaviy natija|Kompaniyaning sof foydasi Agenus Inc|Kompaniya foydasi CLYM (Climb Bio, Inc)|Sof foyda ZURA|atyrpharma.com (ATYR) - Yillik sof foyda|Kompaniyaning sof foydasi Adagene Inc. ADAG|Sof moliyaviy natija ImageneBio (IMA)|STTK: Sof daromad|Yakuniy foyda EQ (Equillium, Inc.)|CNTB: Sof foyda|IMUX - Sof moliyaviy natija|Kompaniyaning sof foydasi Atara Biotherapeutics, Inc.|Kompaniya foydasi IFRX (InflaRx GmbH)|Sof foyda XFOR|Sof daromad adicetbio.com ACET|Celularity - Sof daromad|Sof moliyaviy natija inmunebio.com (INMB)|Barinthus Biotherapeutics plc - Sof foyda|Kompaniyaning sof daromadi Kezar Life Sciences Inc.|SAB Biotherapeutics, Inc (SABS) - Kompaniyaning sof foydasi|Kompaniya foydasi AKTX|ENLV (Enlivex Therapeutics Ltd) - Sof foyda|QTTB - Yillik sof foyda|Kompaniyaning sof foydasi GeoVax (GOVX)|Edesa Biotech Inc - Kompaniya foydasi|Kompaniyaning sof foydasi iBio Corp IBIO|CARM (Carisma Therapeutics Inc) - Soliqdan keyingi foyda|XTL Biopharmaceuticals - Sof foyda|Yakuniy foyda BOLT (Bolt Biotherapeutics)|HCWB: Sof foyda|Aptevo Therapeutics Inc. (APVO) - Sof foyda|Kompaniyaning sof foydasi AIM ImmunoTech|ADTX: Yakuniy foyda|Kompaniyaning sof foydasi GRI Bio, Inc. (GRI)|Sof daromad xortx.com XRTX|Sof foyda HIND (Vyome Holdings)|Sof foyda Revelation Biosciences Inc REVB|INDP: Sof daromad|Yakuniy foyda SCNI (BiondVax Pharmaceuticals)|CALI: Sof foyda|AFMD - Sof moliyaviy natija|Kompaniyaning sof foydasi Allakos Inc|Sof daromad HOOKIPA (HOOK)|Kompaniyaning sof foydasi IGM Biosciences, Inc. (IGMS)|Sof daromad iTeos Pharma ITOS|Ocean Biomedical, Inc. - Sof daromad|Sof foyda tcbiopharm.com TCBP|THRD - Kompaniyaning sof foydasi